← Leaderboards
George Coukos
University Of Pennsylvania
$10,781,200
Attributed
$12,402,159
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$10,802,159 · 8
FDA$1,600,000 · 1
By mechanism
R01$7,520,511 · 4
P50$3,050,542 · 2
P01$1,135,106 · 2
R21$696,000 · 1
Top collaborators
- Andrew K Godwin5 shared
- Carl H. June5 shared
- Michael V. Seiden5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Joseph G Sodroski$53,351,794
- Irwin M Chaiken$15,499,914
- Ronald G Collman$30,299,814
- Mortimer Poncz$48,626,684
- Hydar Ali$12,367,036
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Robert C Bast · University Of Texas Md Anderson Can Ctr$22,987,143
Research focus
Malignant Neoplasm Of OvaryTumorImmunotherapyT-LymphocyteTumor GrowthTumor AntigensIn VitroEpithelial Ovarian CancerIn VivoClinicBaseLaboratoriesProgramsMediatingImmuneAntibodiesPlayNeoplastic CellMalignant NeoplasmsAttenuatedOvarian CarcinomaAutologousAffectImmune Response
Grant awards (37)
Transformative personalized vascular disrupting cancer immunotherapy$562,946
R01 · FY2014 · CA · contact PI
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer$400,000
R01 · FY2014 · FD · contact PI
Transformative personalized vascular disrupting cancer immunotherapy$562,439
R01 · FY2013 · CA · contact PI
Advancing T cell Therapy for Ovarian Cancer$529,359
P50 · FY2013 · CA · contact PI
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer$400,000
R01 · FY2013 · FD · contact PI
Administrative Core$113,106
P50 · FY2013 · CA
Transformative personalized vascular disrupting cancer immunotherapy$597,229
R01 · FY2012 · CA · contact PI
Advancing T cell Therapy for Ovarian Cancer$450,053
P50 · FY2012 · CA · contact PI
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer$400,000
R01 · FY2012 · FD · contact PI
Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer$348,000
R21 · FY2012 · CA · contact PI
Administrative Core$51,659
P50 · FY2012 · CA
Transformative personalized vascular disrupting cancer immunotherapy$615,146
R01 · FY2011 · CA · contact PI
Advancing T cell Therapy for Ovarian Cancer$516,260
P50 · FY2011 · CA · contact PI
Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer$348,000
R21 · FY2011 · CA · contact PI
COMPLEMENT IN CANCER ESTABLISHMENT AND GROWTH$284,730
P01 · FY2011 · AI · contact PI
Administrative Core$141,118
P50 · FY2011 · CA
Transformative personalized vascular disrupting cancer immunotherapy$635,042
R01 · FY2010 · CA · contact PI
Advancing T cell Therapy for Ovarian Cancer$542,075
P50 · FY2010 · CA · contact PI
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors$271,456
R01 · FY2010 · CA · contact PI
Administrative Core$148,187
P50 · FY2010 · CA
COMPLEMENT IN CANCER ESTABLISHMENT AND GROWTH$121,442
P01 · FY2010 · AI · contact PI
Advancing T cell Therapy for Ovarian Cancer$438,669
P50 · FY2009 · CA · contact PI
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors$271,456
R01 · FY2009 · CA · contact PI
COMPLEMENT IN CANCER ESTABLISHMENT AND GROWTH$133,261
P01 · FY2009 · AI · contact PI
Administrative Core$120,056
P50 · FY2009 · CA
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors$99,995
R01 · FY2009 · CA · contact PI
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer$400,000
R01 · FY2008 · FD · contact PI
COMPLEMENT IN CANCER ESTABLISHMENT AND GROWTH$342,004
P01 · FY2008 · AI · contact PI
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors$271,456
R01 · FY2008 · CA · contact PI
Endothelial Regulation of T Cell Homing in Ovarian Carcinoma$285,544
R01 · FY2007 · CA · contact PI
Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors$271,456
R01 · FY2007 · CA · contact PI
Complement in cancer establishment and growth$253,669
P01 · FY2007 · AI · contact PI
Endothelial Regulation of T Cell Homing$294,073
R01 · FY2006 · CA · contact PI
Vascular Leukocytes Induce Treg in Tumors$278,823
R01 · FY2006 · CA · contact PI
Endothelial Regulation of T Cell Homing$301,150
R01 · FY2005 · CA
Endothelial Regulation of T Cell Homing$301,150
R01 · FY2004 · CA
Endothelial Regulation of T Cell Homing$301,150
R01 · FY2003 · CA